- News
News
Welcome to the homepage of AIHTA!
AIHTA is an acadmic non-profit institute. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the AIHTA team.
In the News section you will find our most recent publications: newsletter, project-reports etc. Previous reports you might find via Research areas, Research projects and Repository.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Öffentliche Infrastruktur zur Überwindung des Marktversagens am Arzneimittelmarkt
- Evaluation von digitalen Gesundheitsanwendungen
- Gesundheitsökonomische Bewertung von „Personalisierter Medizin“
- Zahnprophylaxe: Zahnsteinentfernung und Politur
- Soziale Isolation und Einsamkeit im Alter
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning of Medicines - Fact Sheets
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 124 (February 2023)
Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency)
Article
HTA-Information Service Rapid Reviews
Since 2023, the Austrian Institute for Health Technology Assessment (AIHTA) is supporting the decisions of Austrian social insurance funds with short evidence syntheses as well as those of hospital providers with factsheets on new, expensive medicines. The aim is to support these decisions on medical services with evidence. The best available evidence from current reviews and clinical trials is summarised.
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: EU-Projekt zur Entwicklung von Methoden zur Preisgestaltung teurer Medikamente: HI-PRIX
- Implementierungsstrategien zur Verbesserung schulischer Gesundheitsförderung
- Methoden zur Identifikation von Patient*innenbedarfen
- Gesundheitsbezogene Lebensqualität: EQ-5D-5L-Validierung für Belgien
- Feldenkrais-Methode bei Beweglichkeitsstörungen
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning of Medicines - Fact Sheets
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 123 (February 2023)
Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
Announcement
Horizon Scanning of Medicines - Fact Sheets
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 121 (February 2023)
Nadofaragen Firadenovec (Adstiladrin®) for Bladder cancer
Fact Sheet No. 122 (February 2023)
Oportuzumab monatox (Vicineum®) for Bladder cancer
Project / HTA-methods & steering instruments
Transparency: Sponsoring of patient initiatives 2021, update
Project leaders: Claudia Wild
Project team: Nikolaus Gregor-Patera
Duration: February 2023 – April 2023
AIHTA - Project „Transparency“
Announcement
Horizon Scanning of Medicines - Fact Sheets
We are pleased to introduce you four new Fact Sheets.
Fact Sheet No. 117 (February 2023)
Olaparib (Lynparza®) for mCRPC
Fact Sheet No. 118 (February 2023)
Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) for HCC
Fact Sheet No. 119 (February 2023)
Tremelimumab (Tremelimumab AstraZeneca®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC
Fact Sheet No. 120 (February 2023)
Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer
Newsletter
Note: this content is only available in German.
Inhalt
- Editorial: Informationstransparenz im Gesundheitswesen
- Modelle zur Prävention und Versorgung peripartaler psychischer Erkrankungen
- Entscheidungskompetenz bei Menschen mit Demenz oder psychischen Erkrankungen
- Myalgische Enzephalomyelitis/Chronisches Fatigue-Syndrom (ME/CFS)
- Vertebroplastie/Kyphoplastie bei schmerzhaften osteoporotischen vertebralen Kompressionsfrakturen
- Termine
- Themen-Vorschau
Announcement
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce our two new HSO Fact Sheets.
Fact Sheet No. 115 (December 2022)
Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma
Fact Sheet No. 116 (December2022)
Durvalumab (Imfinzi®) for Biliary tract cancer
